Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis

Immunologic Research

Volumn 56, Issue 2-3, 2013, Pages 398-412

  Proal, Amy D ^a   Albert, Paul J ^b   Marshall, Trevor G ^a,c   Blaney, Greg P ^d   Lindseth, Inge A ^a,e  

^a Autoimmunity Research Foundation   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MURDOCH UNIVERSITY   (Australia)

^d Stillpoint Centre   (Canada)

^e NONE   (Norway)

Author keywords

Chronic fatigue syndrome; Immunopathology; Immunostimulation; Infection; Microbiome

Indexed keywords

AMOXICILLIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; AUTOANTIBODY; AZITHROMYCIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFALEXIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; LITHIUM; MINOCYCLINE; OLMESARTAN; PLACEBO; RITUXIMAB; THYROID HORMONE; VENLAFAXINE; VITAMIN D RECEPTOR;

ANTIMICROBIAL ACTIVITY; ARTICLE; BRONCHITIS; CHRONIC DISEASE; CHRONIC FATIGUE SYNDROME; CHRONIC SINUSITIS; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROBACTERIACEAE; EPSTEIN BARR VIRUS; GENOME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNE DYSREGULATION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; LOW DRUG DOSE; METABOLIC DISORDER; METAGENOME; MICROBIAL COMMUNITY; MICROBIOME; MOLECULAR MIMICRY; MYCOPLASMA; PATHOGENESIS; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; SORE THROAT; SPECIES DIVERSITY; STRESS;

COINFECTION; DYSBIOSIS; FATIGUE SYNDROME, CHRONIC; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; IMMUNIZATION; IMMUNOSUPPRESSION; INFECTION; METAGENOME; MICROBIOTA; MODELS, BIOLOGICAL; RECEPTORS, CALCITRIOL;

EID: 84879550703     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8413-z     Document Type: Article

References (99)

1. Komaroff AL, Cho TA. Role of infection and neurologic dysfunction in chronic fatigue syndrome. Semin Neurol. 2011;31(3):325-37.
2. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121(12):953-9. (Pubitemid 24370860)
3. U.S. Food and Drug Administration. Drug development for myalgic encephalomyelitis and chronic fatigue syndrome (ME and CFS). 2012. http://www.fda.gov/downloads/Drugs/NewsEvents/UCM320310.pdf.
4. Fluge O, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, et al. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One. 2011;6(10):e26358. doi: 10.1371/journal.pone.0026358.
5. Ortega-Hernandez OD, Shoenfeld Y. Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence? Ann N Y Acad Sci. 2009;1173:600-9. doi: 10.1111/j.1749-6632.2009.04799.x.
6. Moriyama K, Ando C, Tashiro K, Kuhara S, Okamura S, Nakano S, et al. Polymerase chain reaction detection of bacterial 16S rRNA gene in human blood. Microbiol Immunol. 2008;52(7):375-82. doi: 10.1111/j.1348-0421.2008.00048.x.
7. Nikkari S, McLaughlin IJ, Bi W, Dodge DE, Relman DA. Does blood of healthy subjects contain bacterial ribosomal DNA? J Clin Microbiol. 2001;39(5):1956-9. doi: 10.1128/jcm.39.5.1956-1959.2001. (Pubitemid 32417051)
8. Katon W, Russo J, Ashley RL, Buchwald D. Infectious mononucleosis: psychological symptoms during acute and subacute phases of illness. Gen Hosp Psychiatry. 1999;21(1):21-9. (Pubitemid 29102701)
9. Benjamin JE, Hoyt RC. Disability following postvaccinal (yellow fever) hepatitis. J Am Med Assoc. 1945;128(5):319-24.
10. Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575. doi: 10.1136/bmj.38933.585764.AE. (Pubitemid 44433631)
11. Naess H, Nyland M, Hausken T, Follestad I, Nyland HI. Chronic fatigue syndrome after Giardia enteritis: clinical characteristics, disability and long-term sickness absence. BMC Gastroenterol. 2012;12:13. doi: 10.1186/1471-230x-12-13.
12. Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome. In Vivo. 2004;18(2):101-6. (Pubitemid 38488991)
13. Lerner AM, Dworkin HJ, Sayyed T, Chang CH, Fitzgerald JT, Beqaj S, et al. Prevalence of abnormal cardiac wall motion in the cardiomyopathy associated with incomplete multiplication of Epstein-barr Virus and/or cytomegalovirus in patients with chronic fatigue syndrome. In Vivo. 2004;18(4):417-24. (Pubitemid 39199985)
14. Fremont M, Metzger K, Rady H, Hulstaert J, De Meirleir K. Detection of herpesviruses and parvovirus B19 in gastric and intestinal mucosa of chronic fatigue syndrome patients. In Vivo. 2009;23(2):209-13.
15. Nijs J, Nicolson GL, De Becker P, Coomans D, De Meirleir K. High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Examination of four Mycoplasma species in blood of chronic fatigue syndrome patients. FEMS Immunol Med Microbiol. 2002;34(3):209-14. (Pubitemid 35335521)
16. Clamp M, Fry B, Kamal M, Xie X, Cuff J, Lin MF, et al. Distinguishing protein-coding and noncoding genes in the human genome. Proc Natl Acad Sci USA. 2007;104(49):19428-33. doi: 10.1073/pnas.0709013104.
17. Reyes A, Haynes M, Hanson N, Angly FE, Heath AC, Rohwer F, et al. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature. 2010;466(7304):334-8. doi: 10.1038/nature09199.
18. Pride DT, Salzman J, Haynes M, Rohwer F, Davis-Long C, White RA 3rd, et al. Evidence of a robust resident bacteriophage population revealed through analysis of the human salivary virome. ISME J. 2012;6(5):915-26. doi: 10.1038/ismej.2011.169.
19. Nelson KE, Weinstock GM, Highlander SK, Worley KC, Creasy HH, Wortman JR, et al. A catalog of reference genomes from the human microbiome. Science. 2010;328(5981):994-9. doi: 10.1126/science.1183605.
20. Nasidze I, Li J, Quinque D, Tang K, Stoneking M. Global diversity in the human salivary microbiome. Genome Res. 2009;19(4):636-43. doi: 10.1101/gr.084616.108.
21. McDonnell M, Liang Y, Noronha A, Coukos J, Kasper DL, Farraye FA, et al. Systemic Toll-like receptor ligands modify B-cell responses in human inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(1):298-307. doi: 10.1002/ibd.21424.
22. Kozarov E. Bacterial invasion of vascular cell types: vascular infectology and atherogenesis. Future Cardiol. 2012;8(1):123-38. doi: 10.2217/fca.11.75.
23. Rafferty B, Dolgilevich S, Kalachikov S, Morozova I, Ju J, Whittier S, et al. Cultivation of Enterobacter hormaechei from human atherosclerotic tissue. J Atheroscler Thromb. 2011;18(1):72-81.
24. Amar J, Serino M, Lange C, Chabo C, Iacovoni J, Mondot S, et al. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia. 2011;54(12):3055-61. doi: 10.1007/s00125-011-2329-8.
25. DiGiulio DB, Romero R, Amogan HP, Kusanovic JP, Bik EM, Gotsch F, et al. Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS One. 2008;3(8):e3056.
26. Hood L. Tackling the microbiome. Science. 2012;336(6086):1209. doi: 10.1126/science.1225475.
27. Mondot S, Kang S, Furet JP, de Carcer AD, McSweeney C, Morrison M, et al. Highlighting new phylogenetic specificities of Crohn's disease microbiota. Inflamm Bowel Dis. 2011;17(1):185-92. doi: 10.1002/ibd.21436.
28. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22(5):512-9, e114-5. doi: 10.1111/j.1365-2982.2009.01427.x.
29. Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat Rev Rheumatol. 2011;7(10):569-78. doi: 10.1038/nrrheum.2011.121.
30. Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G et al. Toward defining the autoimmune microbiome for type 1 diabetes. Isme J. 2010. doi: 10.1038/ismej.2010.92.
31. Burcelin R, Serino M, Chabo C, Blasco-Baque V, Amar J. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol. 2011;48(4):257-73. doi: 10.1007/s00592-011-0333-6.
32. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012;13(4):260-70. doi: 10.1038/nrg3182.
33. McMahon AW, Schmitt P, Patterson JF, Rothman E. Personality differences between inflammatory bowel disease patients and their healthy siblings. Psychosom Med. 1973;35(2):91-103.
34. Lepage P, Hasler R, Spehlmann ME, Rehman A, Zvirbliene A, Begun A, et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology. 2011;141(1):227-36. doi: 10.1053/j.gastro.2011.04.011.
35. Kilic A, Gulec MY, Gul U, Gulec H. Temperament and character profile of patients with psoriasis. J Eur Acad Dermatol Venereol. 2008;22(5):537-42. doi: 10.1111/j.1468-3083.2007.02460.x. (Pubitemid 351541046)
36. Gao Z, Tseng CH, Strober BE, Pei Z, Blaser MJ. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One. 2008;3(7):e2719. doi: 10.1371/journal.pone.0002719.
37. Knapp PH, Nemetz SJ. Personality variations in bronchial asthma; a study of forty patients: notes on the relationship to psychosis and the problem of measuring maturity. Psychosom Med. 1957;19(6):443-65.
38. Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, Bonnelykke K, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med. 2007;357(15):1487-95. doi: 10.1056/NEJMoa052632. (Pubitemid 47572634)
39. Chang AH, Parsonnet J. Role of bacteria in oncogenesis. Clin Microbiol Rev. 2010;23(4):837-57. doi: 10.1128/cmr.00012-10.
40. Plottel CS, Blaser MJ. Microbiome and malignancy. Cell Host Microbe. 2011;10(4):324-35. doi: 10.1016/j.chom.2011.10.003.
41. Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012. doi: 10.1126/science.1224820.
42. Caporaso JG, Lauber CL, Costello EK, Berg-Lyons D, Gonzalez A, Stombaugh J, et al. Moving pictures of the human microbiome. Genome Biol. 2011;12(5):R50. doi: 10.1186/gb-2011-12-5-r50.
43. Santiago GL, Cools P, Verstraelen H, Trog M, Missine G, El Aila N, et al. Longitudinal study of the dynamics of vaginal microflora during two consecutive menstrual cycles. PLoS One. 2011;6(11):e28180. doi: 10.1371/journal.pone. 0028180.
44. Bogaert D, Keijser B, Huse S, Rossen J, Veenhoven R, van Gils E, et al. Variability and diversity of nasopharyngeal microbiota in children: a metagenomic analysis. PLoS One. 2011;6(2):e17035. doi: 10.1371/journal.pone. 0017035.
45. Booijink CC, El-Aidy S, Rajilic-Stojanovic M, Heilig HG, Troost FJ, Smidt H, et al. High temporal and inter-individual variation detected in the human ileal microbiota. Environ Microbiol. 2010;12(12):3213-27. doi: 10.1111/j.1462-2920.2010.02294.x.
46. Proal AD, Albert PJ, Marshall TG. Autoimmune disease and the human metagenome. In: Nelson KE, editor. Metagenomics of the human body. New York: Springer; 2010. p. 231-75.
47. Juillard F, Bazot Q, Mure F, Tafforeau L, Macri C, Rabourdin-Combe C, et al. Epstein-Barr virus protein EB2 stimulates cytoplasmic mRNA accumulation by counteracting the deleterious effects of SRp20 on viral mRNAs. Nucleic Acids Res. 2012;40(14):6834-49. doi: 10.1093/nar/gks319.
48. Hacker G, Kirschnek S, Fischer SF. Apoptosis in infectious disease: how bacteria interfere with the apoptotic apparatus. Med Microbiol Immunol. 2006;195(1):11-9. doi: 10.1007/s00430-005-0239-4. (Pubitemid 43081602)
49. Meresse S, Steele-Mortimer O, Moreno E, Desjardins M, Finlay B, Gorvel JP. Controlling the maturation of pathogen-containing vacuoles: a matter of life and death. Nat Cell Biol. 1999;1(7):E183-8. doi: 10.1038/15620.
50. Muller MP, Peters H, Blumer J, Blankenfeldt W, Goody RS, Itzen A. The legionella effector protein DrrA AMPylates the membrane traffic regulator Rab1b. Science. 2010. doi: 10.1126/science.1192276.
51. Salinas-Carmona MC, Zuniga JM, Perez-Rivera LI, Segoviano-Ramirez JC, Vazquez-Marmolejo AV. Nocardia brasiliensis Modulates IFN-gamma, IL-10, and IL-12 cytokine production by macrophages from BALB/c Mice. J Interferon Cytokine Res. 2009;29(5):263-71. doi: 10.1089/jir.2008.0059.
52. Zhao L, Shen J. Whole-body systems approaches for gut microbiota-targeted, preventive healthcare. J Biotechnol. 2010;149(3):183-90. doi: 10.1016/j.jbiotec.2010.02.008.
53. Xu Y, Xie J, Li Y, Yue J, Chen J, Chunyu L, et al. Using a cDNA microarray to study cellular gene expression altered by Mycobacterium tuberculosis. Chin Med J. 2003;116(7):1070-3. (Pubitemid 36975163)
54. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol. 2007;179(4):2060-3.
55. Sonawane A, Santos JC, Mishra BB, Jena P, Progida C, Sorensen OE, et al. Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages. Cell Microbiol. 2011;13(10):1601-17. doi: 10.1111/j.1462-5822.2011. 01644.x.
56. Nickel D, Busch M, Mayer D, Hagemann B, Knoll V, Stenger S. Hypoxia triggers the expression of human beta defensin 2 and antimicrobial activity against Mycobacterium tuberculosis in human macrophages. J Immunol. 2012;188(8):4001-7. doi: 10.4049/jimmunol.1100976.
57. Corrales-Garcia LL, Possani LD, Corzo G. Expression systems of human beta-defensins: vectors, purification and biological activities. Amino Acids. 2011;40(1):5-13. doi: 10.1007/s00726-010-0493-7.
58. Krishnakumari V, Rangaraj N, Nagaraj R. Antifungal activities of human beta-defensins HBD-1 to HBD-3 and their C-terminal analogs Phd1 to Phd3. Antimicrob Agents Chemother. 2009;53(1):256-60. doi: 10.1128/AAC.00470-08.
59. Nakatsuji T, Gallo RL. Antimicrobial peptides: old molecules with new ideas. J Invest Dermatol. 2012;132(3 Pt 2):887-95. doi: 10.1038/jid.2011.387.
60. Yenamandra SP, Lundin A, Arulampalam V, Yurchenko M, Pettersson S, Klein G, et al. Expression profile of nuclear receptors upon Epstein - Barr virus induced B cell transformation. Exp Oncol. 2009;31(2):92-6.
61. Liu PT, Wheelwright M, Teles R, Komisopoulou E, Edfeldt K, Ferguson B, et al. MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy. Nat Med. 2012;18(2):267-73. doi: 10.1038/nm.2584.
62. Marshall TG. Bacterial capnine blocks transcription of human antimicrobial peptides. In: Third international conference on metagenomics; July 11-13; San Diego, CA 2007.
63. Coughlan CA, Chotirmall SH, Renwick J, Hassan T, Boon Low T, Bergsson G et al. The effect of Aspergillus fumigatus infection on Vitamin D receptor expression in cystic fibrosis. Am J Respir Crit Care Med. 2012. doi: 10.1164/rccm.201203-0478OC.
64. Blaney GP, Albert PJ, Proal AD. Vitamin D metabolites as clinical markers in autoimmune and chronic disease. Ann N Y Acad Sci. 2009;1173:384-90. doi: 10.1111/j.1749-6632.2009.04875.x.
65. Marshall TG. Vitamin D discovery outpaces FDA decision making. BioEssays. 2008;30(2):173-82. (Pubitemid 351196952)
66. Proal AD, Albert PJ, Marshall TG. Dysregulation of the vitamin D nuclear receptor may contribute to the higher prevalence of some autoimmune diseases in women. Ann N Y Acad Sci. 2009;1173:252-9. doi: 10.1111/j.1749-6632.2009.04672.x.
67. Silverman MN, Heim CM, Nater UM, Marques AH, Sternberg EM. Neuroendocrine and immune contributors to fatigue. PM R. 2010;2(5):338-46. doi: 10.1016/j.pmrj.2010.04.008.
68. Brahmachary M, Schonbach C, Yang L, Huang E, Tan SL, Chowdhary R, et al. Computational promoter analysis of mouse, rat and human antimicrobial peptide-coding genes. BMC Bioinf. 2006;7(Suppl 5):S8.
69. Krishnadev O, Srinivasan N. Prediction of protein-protein interactions between human host and a pathogen and its application to three pathogenic bacteria. Int J Biol Macromol. 2011;48(4):613-9. doi: 10.1016/j.ijbiomac.2011. 01.030.
70. Schutzer SE, Angel TE, Liu T, Schepmoes AA, Clauss TR, Adkins JN, et al. Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome. PLoS One. 2011;6(2):e17287. doi: 10.1371/journal.pone.0017287.
71. Oakley BB, Fiedler TL, Marrazzo JM, Fredricks DN. Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosis. Appl Environ Microbiol. 2008;74(15):4898-909. doi: 10.1128/aem.02884-07.
72. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55(2):205-11. doi: 10.1136/gut.2005.073817. (Pubitemid 43117279)
73. Maes M, Mihaylova I, Leunis JC. Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability. J Affect Disord. 2007;99(1-3):237-40. doi: 10.1016/j.jad.2006.08.021.
74. Gonzalez A, Stombaugh J, Lozupone C, Turnbaugh PJ, Gordon JI, Knight R. The mind-body-microbial continuum. Dialogues Clin Neurosci. 2011;13(1):55-62.
75. Bassi N, Amital D, Amital H, Doria A, Shoenfeld Y. Chronic fatigue syndrome: characteristics and possible causes for its pathogenesis. Isr Med Assoc J. 2008;10(1):79-82. (Pubitemid 351649474)
76. Konstantinov K, von Mikecz A, Buchwald D, Jones J, Gerace L, Tan EM. Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. J Clin Invest. 1996;98(8):1888-96. doi: 10.1172/JCI118990. (Pubitemid 26359207)
77. Lekakh IV, Rott GM, Poverennyi AM. "Masked" autoantibodies from the serum of healthy blood donors cross-reacting with DNA and bacterial lipopolysaccharides. Biull Eksp Biol Med. 1991;111(5):516-8.
78. Barzilai O, Ram M, Shoenfeld Y. Viral infection can induce the production of autoantibodies. Curr Opin Rheumatol. 2007;19(6):636-43. (Pubitemid 47530886)
79. Berlin T, Zandman-Goddard G, Blank M, Matthias T, Pfeiffer S, Weis I, et al. Autoantibodies in nonautoimmune individuals during infections. Ann N Y Acad Sci. 2007;1108:584-93. (Pubitemid 47528772)
80. Tanaka S, Kuratsune H, Hidaka Y, Hakariya Y, Tatsumi KI, Takano T, et al. Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int J Mol Med. 2003;12(2):225-30.
81. Al-Mofada SM. Neonatal Haemophilus influenzae infections. J Infect. 1994;29(3):283-7. (Pubitemid 24365184)
82. Merino G, Carranza-Lira S, Murrieta S, Rodriguez L, Cuevas E, Moran C. Bacterial infection and semen characteristics in infertile men. Arch Androl. 1995;35(1):43-7.
83. Weyermann M, Rothenbacher D, Brenner H. Acquisition of Helicobacter pylori infection in early childhood: independent contributions of infected mothers, fathers, and siblings. Am J Gastroenterol. 2009;104(1):182-9. doi: 10.1038/ajg.2008.61.
84. Sarkola M, Rintala M, Grenman S, Syrjanen S. Human papillomavirus DNA detected in breast milk. Pediatr Infect Dis J. 2008;27(6):557-8. doi: 10.1097/INF.0b013e318169ef47.
85. Biasucci G, Rubini M, Riboni S, Morelli L, Bessi E, Retetangos C. Mode of delivery affects the bacterial community in the newborn gut. Early Human Dev. 2010;86(Suppl 1):13-5. doi: 10.1016/j.earlhumdev.2010.01.004.
86. Kembel SW, Jones E, Kline J, Northcutt D, Stenson J, Womack AM, et al. Architectural design influences the diversity and structure of the built environment microbiome. ISME J. 2012;6(8):1469-79. doi: 10.1038/ismej.2011.211.
87. Pinto A, Xi C, Raskin L. Bacterial community structure in the drinking water microbiome is governed by filtration processes. Environ Sci Technol. 2012.
88. Vignaroli C, Zandri G, Aquilanti L, Pasquaroli S, Biavasco F. Multidrug-resistant enterococci in animal meat and faeces and co-transfer of resistance from an Enterococcus durans to a human Enterococcus faecium. Curr Microbiol. 2011;62(5):1438-47. doi: 10.1007/s00284-011-9880-x.
89. U.S. Census Bureau. Table 1308. U.S. exports and general imports by selected SITC Commodity Groups: 2000 to 2010. Statistical Abstract of the United States: 2012. 2012.
90. FAO Trade and Markets Division. Food outlook global market analysis. 2010. http://www.fao.org/docrep/013/al969e/al969e00.pdf.
91. Airbus. Global Market forecast 2011-2030 delivering the future. 2011. http://goo.gl/PQ2rv.
92. Padilla ML, Schilero GJ, Teirstein AS. Donor-acquired sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19(1):18-24. (Pubitemid 34298490)
93. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47(2):187-98. doi: 10.1053/j.seminhematol.2010.01.002.
94. Proal AD, Albert PJ, Blaney GP, Lindseth IA, Benediktsson C, Marshall TG. Immunostimulation in the era of the metagenome. Cell Mol Immunol. 2011;8(3):213-25. doi: 10.1038/cmi.2010.77.
95. Marshall TG. Molecular static and dynamic analyses reveal flaw in murine model used by US FDA to detect drug carcinogenicity. Nature Precedings. 2007. http://precedings.nature.com/documents/52/version/1.
96. Daiichi Sankyo. Benicar (olmesartan medoxomil) tablets. 2011. http://www.benicar.com/pdf/prescribing-information.pdf.
97. Proud D, Turner RB, Winther B, Wiehler S, Tiesman JP, Reichling TD, et al. Gene expression profiles during in vivo human rhinovirus infection: insights into the host response. Am J Respir Crit Care Med. 2008;178(9):962-8. doi: 10.1164/rccm.200805-670OC.
98. Tsang CS, Samaranayake LP. Immune reconstitution inflammatory syndrome after highly active antiretroviral therapy: a review. Oral Dis. 2010;16(3):248-56. doi: 10.1111/j.1601-0825.2009.01628.x.
99. Agborsangaya CB, Lehtinen T, Toriola AT, Pukkala E, Surcel HM, Tedeschi R, et al. Association between Epstein-Barr virus infection and risk for development of pregnancy-associated breast cancer: joint effect with vitamin D? Eur J Cancer. 2011;47(1):116-20. doi: 10.1016/j.ejca.2010.07.006.